Bezafibrate
| Bezafibrate | |
|---|---|
| Bezafibrate.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Bezafibrate is a fibrate medication used to treat hyperlipidemia, a condition characterized by elevated levels of lipids in the blood. It is primarily used to lower cholesterol and triglyceride levels, thereby reducing the risk of cardiovascular disease.
Mechanism of Action[edit]
Bezafibrate works by activating peroxisome proliferator-activated receptors (PPARs), which are nuclear receptors that regulate the expression of genes involved in lipid metabolism. By activating PPARs, bezafibrate increases the oxidation of fatty acids and enhances the clearance of triglycerides from the bloodstream. This leads to a reduction in very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) levels, while increasing high-density lipoprotein (HDL) levels.
Clinical Uses[edit]
Bezafibrate is indicated for the treatment of various forms of hyperlipidemia, including:
- Hypercholesterolemia
- Hypertriglyceridemia
- Mixed hyperlipidemia
It is often prescribed when dietary measures and other non-pharmacological interventions have failed to adequately control lipid levels.
Side Effects[edit]
Common side effects of bezafibrate include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Other potential side effects include:
- Myopathy
- Liver enzyme abnormalities
- Gallstones
Patients are advised to report any unexplained muscle pain or weakness, as this could indicate a serious condition known as rhabdomyolysis.
Contraindications[edit]
Bezafibrate is contraindicated in patients with:
- Severe liver disease
- Severe renal impairment
- Pre-existing gallbladder disease
Drug Interactions[edit]
Bezafibrate may interact with other medications, including:
- Statins: Increased risk of myopathy and rhabdomyolysis
- Anticoagulants: Enhanced anticoagulant effect
Synthesis[edit]
The synthesis of bezafibrate involves the reaction of 4-chlorobenzoyl chloride with 2-(4-hydroxyphenyl)ethylamine to form an amide intermediate. This intermediate is then reacted with 2-bromo-2-methylpropanoic acid to yield bezafibrate.
Related Pages[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
